| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 30th Annual J.P. Morgan Healthcare...
-
Dec 27, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Nov 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its...
-
Nov 15, 2011
Perrigo Company (NASDAQ: PRGO; TASE) today announced it received Food and Drug Administration (FDA) clearance to market and distribute infant formula...
-
Nov 8, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai)...
-
Nov 7, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine...
-
Nov 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for...
-
Nov 1, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl...
-
Oct 27, 2011-- Fiscal first quarter revenue from continuing operations increased $84 million, or 13%, to a record $725 million
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 24, 2011. Perrigo's Chairman and CEO Joseph...
-
Oct 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on December...